STOCK TITAN
  1. Home
  2. SEC Filings
  3. LYCA
  4. [Form 4] Lycia Therapeutics, Inc. Insider Trading Activity

Lycia Therapeutics: Funds buy 25,004 shares

The ownership footnotes identify the fund holders and explain how management members may be deemed beneficial owners.

Available on EDGAR Accepted by SEC EDGAR
Filing Impact
(High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. (LYCA) reported five indirect purchases by funds associated with reporting persons, totaling 25,004 common shares from October 28 through October 30, 2026. The purchases were 10,570 shares at a weighted average $25.23 and 4,430 at $25.97 on October 28; 1,000 at $26.33 on October 29; and 8,804 at $26.27 and 200 at $26.86 on October 30.

The ownership footnotes identify Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and Venrock Healthcare Capital Partners EG, L.P. as funds holding purchased shares. Bong Y. Koh and Nimish P. Shah are voting members of the management entities; the footnotes say they may be deemed to beneficially own shares and disclaim beneficial ownership except for indirect pecuniary interests. No Rule 10b5-1 plan is reported.

Insider Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management EG, LLC, Venrock Healthcare Capital Partners XP, L.P., VHCP Management XP, LLC, Koh Bong Y, Shah Nimish P
Role 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought 25,004 shs ($645K)
Increase in Position 0.37%
Type Security Shares Price Value
Purchase Common Stock F13, F14, F15, F4, F5, F6 8,804 $26.27 $231K
Purchase Common Stock F16, F17, F18, F4, F5, F6 200 $26.86 $5K
Purchase Common Stock F10, F11, F12, F4, F5, F6 1,000 $26.33 $26K
Purchase Common Stock F1, F2, F3, F4, F5, F6 10,570 $25.23 $267K
Purchase Common Stock F7, F8, F9, F4, F5, F6 4,430 $25.97 $115K
Holdings After Transaction: Common Stock — 6,850,237 shares (Indirect, By Funds)
Holdings Before and After: Common Stock, 6,825,233 to 6,850,237 shares (Indirect, By Funds)
Footnotes (18)
  1. F1. Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
  2. F2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  3. F3. Consists of (i) 1,762,936 shares held by VHCP3; (ii) 176,435 shares held by VHCP Co-3; (iii) 4,244,642 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
  4. F4. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  5. F5. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  6. F6. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
  7. F7. Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG.
  8. F8. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  9. F9. Consists of (i) 1,764,949 shares held by VHCP3; (ii) 176,637 shares held by VHCP Co-3; (iii) 4,246,857 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  10. F10. Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG.
  11. F11. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  12. F12. Consists of (i) 1,765,404 shares held by VHCP3; (ii) 176,682 shares held by VHCP Co-3; (iii) 4,247,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  13. F13. Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG.
  14. F14. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  15. F15. Consists of (i) 1,769,405 shares held by VHCP3; (ii) 177,083 shares held by VHCP Co-3; (iii) 4,251,759 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
  16. F16. Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG.
  17. F17. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
  18. F18. Consists of (i) 1,769,496 shares held by VHCP3; (ii) 177,092 shares held by VHCP Co-3; (iii) 4,251,859 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
Total shares purchased 25,004 shares Five purchases from October 28 through October 30, 2026
Purchase shares and weighted-average price 10,570 shares at $25.23 per share October 28, 2026
Purchase shares and weighted-average price 4,430 shares at $25.97 per share October 28, 2026
Purchase shares and weighted-average price 1,000 shares at $26.33 per share October 29, 2026
Purchase shares and weighted-average price 8,804 shares at $26.27 per share October 30, 2026
Purchase shares and weighted-average price 200 shares at $26.86 per share October 30, 2026
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership regulatory
"expressly disclaims beneficial ownership over these shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
indirect pecuniary interest regulatory
"except to the extent of its or his indirect pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA shares did the funds purchase?
The funds purchased 25,004 LYCA shares across five reported purchases from October 28 through October 30, 2026. Purchases were 10,570 shares at a weighted average $25.23, 4,430 at $25.97, 1,000 at $26.33, 8,804 at $26.27, and 200 at $26.86 per share.

What fund holdings were reported after the October 30, 2026 LYCA purchases?
Reported holdings were 1,769,496 shares for Venrock Healthcare Capital Partners III, L.P.; 177,092 for VHCP Co-Investment Holdings III, LLC; 4,251,859 for Venrock Healthcare Capital Partners EG, L.P.; and 651,790 for Venrock Healthcare Capital Partners XP, L.P.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock10/28/2026P10,570(1)A$25.23(2)6,835,803(3)IBy Funds(4)(5)(6)
Common Stock10/28/2026P4,430(7)A$25.97(8)6,840,233(9)IBy Funds(4)(5)(6)
Common Stock10/29/2026P1,000(10)A$26.33(11)6,841,233(12)IBy Funds(4)(5)(6)
Common Stock10/30/2026P8,804(13)A$26.27(14)6,850,037(15)IBy Funds(4)(5)(6)
Common Stock10/30/2026P200(16)A$26.86(17)6,850,237(18)IBy Funds(4)(5)(6)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners III, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Co-Investment Holdings III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management III, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners EG, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management EG, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Venrock Healthcare Capital Partners XP, L.P.
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
VHCP Management XP, LLC
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Koh Bong Y
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Shah Nimish P
(Last)(First)(Middle)
C/O VENROCK
7 BRYANT PARK, 23RD FLOOR
(Street)
NEW YORK NEW YORK 10018
(City)(State)(Zip)
UNITED STATES
(Country)
Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. Consists of (i) 4,804 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 481 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 5,285 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
2. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $24.77 to $25.50 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
3. Consists of (i) 1,762,936 shares held by VHCP3; (ii) 176,435 shares held by VHCP Co-3; (iii) 4,244,642 shares held by VHCP EG; and (iv) 651,790 shares held by Venrock Healthcare Capital Partners XP, L.P. ("VHCP XP").
4. VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own the shares held by VHCP3 and VHCP Co-3. Bong Koh and Nimish Shah are the voting members of VHCPM3 and may be deemed to beneficially own these shares. Each of VHCPM3 and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
5. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCP EG and may be deemed to beneficially own the shares held by VHCP EG. Bong Koh and Nimish Shah are the voting members of VHCPMEG and may be deemed to beneficially own these shares. Each of VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
6. VHCP Management XP, LLC ("VHCPMXP") is the general partner of VHCP XP and may be deemed to beneficially own the shares held by VHCP XP. Bong Koh and Nimish Shah are the voting members of VHCPMXP and may be deemed to beneficially own these shares. Each of VHCPMXP and Messrs. Koh and Shah expressly disclaims beneficial ownership over these shares except to the extent of its or his indirect pecuniary interest therein.
7. Consists of (i) 2,013 shares held by VHCP3; (ii) 202 shares held by VHCP Co-3; and (iii) 2,215 shares held by VHCP EG.
8. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.88 to $26.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
9. Consists of (i) 1,764,949 shares held by VHCP3; (ii) 176,637 shares held by VHCP Co-3; (iii) 4,246,857 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
10. Consists of (i) 455 shares held by VHCP3; (ii) 45 shares held by VHCP Co-3; and (iii) 500 shares held by VHCP EG.
11. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.26 to $26.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
12. Consists of (i) 1,765,404 shares held by VHCP3; (ii) 176,682 shares held by VHCP Co-3; (iii) 4,247,357 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
13. Consists of (i) 4,001 shares held by VHCP3; (ii) 401 shares held by VHCP Co-3; and (iii) 4,402 shares held by VHCP EG.
14. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $25.70 to $26.64 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
15. Consists of (i) 1,769,405 shares held by VHCP3; (ii) 177,083 shares held by VHCP Co-3; (iii) 4,251,759 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
16. Consists of (i) 91 shares held by VHCP3; (ii) 9 shares held by VHCP Co-3; and (iii) 100 shares held by VHCP EG.
17. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $26.84 to $26.87 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
18. Consists of (i) 1,769,496 shares held by VHCP3; (ii) 177,092 shares held by VHCP Co-3; (iii) 4,251,859 shares held by VHCP EG; and (iv) 651,790 shares held by VHCP XP.
Venrock Healthcare Capital Partners III, L.P., By: VHCP Management III, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
VHCP Co-Investment Holdings III, LLC, By: VHCP Management III, LLC, Its: Manager, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
VHCP Management III, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
Venrock Healthcare Capital Partners EG, L.P., By: VHCP Management EG, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
VHCP Management EG, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
Venrock Healthcare Capital Partners XP, L.P., By: VHCP Management XP, LLC, Its: General Partner, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
VHCP Management XP, LLC, By: /s/ Sherman G. Souther, Authorized Signatory10/30/2026
Bong Y. Koh, By: /s/ Sherman G. Souther, Attorney-in-Fact10/30/2026
Nimish P. Shah, By: /s/ Sherman G. Souther, Attorney-in-Fact10/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on LYCA

All LYCA news

Trending in the feed

RAYA
ERAYAK Advances Hybrid Power Strategy as Ruike Facility Enters Final Acceptance Phase Open the live feed